{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:11:21Z","timestamp":1649085081599},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/j.medici.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T08:35:45Z","timestamp":1456994145000},"page":"69-78","source":"Crossref","is-referenced-by-count":0,"title":["Multidrug-resistant tuberculosis in Lithuania \u2013 Still a long way ahead"],"prefix":"10.3390","volume":"52","author":[{"given":"Greta","family":"Musteikien\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skaidrius","family":"Miliauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundas","family":"Sakalauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astra","family":"Vitkauskien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"\u017demaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","reference":[{"key":"10.1016\/j.medici.2016.02.002_bib0325","series-title":"European respiratory monograph: tuberculosis","year":"2013"},{"key":"10.1016\/j.medici.2016.02.002_bib0330","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00023211","article-title":"Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients","volume":"38","author":"Whitelaw","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0335","doi-asserted-by":"crossref","first-page":"e1536","DOI":"10.1371\/journal.pone.0001536","article-title":"Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression","volume":"3","author":"Ling","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.medici.2016.02.002_bib0340","first-page":"17","article-title":"Epidemiology of tuberculosis in the EU\/EEA in 2010: monitoring the progress towards tuberculosis elimination","author":"Sandgren","year":"2012","journal-title":"Euro Surveill"},{"key":"10.1016\/j.medici.2016.02.002_bib0345","volume":"vol. 1","author":"Acosta","year":"2015"},{"key":"10.1016\/j.medici.2016.02.002_bib0350","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","article-title":"LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement","volume":"33","author":"Mack","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0355","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1183\/09031936.00077307","article-title":"Clinical and operational value of the extensively drug-resistant tuberculosis definition","volume":"30","author":"Migliori","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0360","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"Michael Rich EJJBEB-CVBJACSC","year":"2014"},{"key":"10.1016\/j.medici.2016.02.002_bib0365","first-page":"10","article-title":"Genetic mutations associated with isoniazid resistance in mycobacterium tuberculosis: a systematic review","author":"Seifert","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medici.2016.02.002_bib0370","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1183\/09031936.00168008","article-title":"Epidemiology and clinical management of XDR-TB: a systematic review by TBNET","volume":"33","author":"Sotgiu","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/CLEP.S35839","article-title":"Extensively drug-resistant tuberculosis: epidemiology and management","volume":"6","author":"Matteelli","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.medici.2016.02.002_bib0380","series-title":"European Centre for Disease Prevention and Control. Annual epidemiological report 2014 \u2013 Respiratory tract infections \u2013 tuberculosis","author":"Hollo","year":"2015"},{"key":"10.1016\/j.medici.2016.02.002_bib0385","unstructured":"ECDC EVIDENCE BRIEF: tuberculosis in Europe: From passive control to active elimination 24AD."},{"key":"10.1016\/j.medici.2016.02.002_bib0390","series-title":"M. Global Tuberculosis Report 2014","author":"Baddeley","year":"2014"},{"key":"10.1016\/j.medici.2016.02.002_bib0395","first-page":"582","article-title":"Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union","volume":"3","author":"Portaels","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0400","unstructured":"http:\/\/data.worldbank.org\/indicator\/SH.TBS.INCD\/countries\/1W-LT?page=2&display=default [accessed 30.05.15]."},{"key":"10.1016\/j.medici.2016.02.002_bib0405","unstructured":"Action plan for the reduction of health inequalities in Lithuania for 2014\u20132023. Available at: https:\/\/www.e-tar.lt\/portal\/lt\/legalAct\/682b6f200d7111e4adf3c8c5d7681e73."},{"key":"10.1016\/j.medici.2016.02.002_bib0410","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1183\/09031936.00133911","article-title":"Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002\u20132008","volume":"39","author":"Balabanova","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0415","unstructured":"https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=EE&LAN=EN&outtype=html [accessed 15.05.15]."},{"key":"10.1016\/j.medici.2016.02.002_bib0420","series-title":"Tuberculosis surveillance and monitoring in Europe 2014","author":"ECDC","year":"2014"},{"key":"10.1016\/j.medici.2016.02.002_bib0425","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(06)69863-2","article-title":"Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis","volume":"368","author":"Aziz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.medici.2016.02.002_bib0430","unstructured":"Lithuania: Vilnius. Lithuanian National Tuberculosis Register. Annual Report. 2014."},{"key":"10.1016\/j.medici.2016.02.002_bib0435","unstructured":"https:\/\/extranet.who.int\/sree\/Reports?.op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=LT&LAN=EN&outtype=html [accessed 27.11.15]."},{"key":"10.1016\/j.medici.2016.02.002_bib0440","unstructured":"https:\/\/extranet.who.int\/sree\/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=EE&LAN=EN&outtype=html [accessed 27.11.15]."},{"key":"10.1016\/j.medici.2016.02.002_bib0445","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0032-1333467","article-title":"Global epidemiology of tuberculosis","volume":"34","author":"Glaziou","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.medici.2016.02.002_bib0450","doi-asserted-by":"crossref","first-page":"e000351","DOI":"10.1136\/bmjopen-2011-000351","article-title":"Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study","volume":"1","author":"Balabanova","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.medici.2016.02.002_bib0455","series-title":"Guidelines for clinical and operational management of drug-resistant tuberculosis","author":"Caminero","year":"2013"},{"key":"10.1016\/j.medici.2016.02.002_bib0460","series-title":"World Health Organization and others","author":"Policy framework for implementing new tuberculosis diagnostics","year":"2010"},{"key":"10.1016\/j.medici.2016.02.002_bib0465","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JCM.42.5.2321-2325.2004","article-title":"Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria","volume":"42","author":"Cruciani","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medici.2016.02.002_bib0470","first-page":"1024","article-title":"Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting","volume":"14","author":"Chihota","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0475","series-title":"Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MT","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.medici.2016.02.002_bib0480","series-title":"Molecular line probe assays for rapid screening of patients at risk of multi drug-resistant tuberculosis (MDR-TB)","author":"World Health Organisation","year":"2008"},{"key":"10.1016\/j.medici.2016.02.002_bib0485","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.actatropica.2011.04.008","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing","volume":"119","author":"Laurenzo","year":"2011","journal-title":"Acta Trop"},{"key":"10.1016\/j.medici.2016.02.002_bib0490","series-title":"Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MT","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.medici.2016.02.002_bib0495","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(11)60438-8","article-title":"Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB\/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study","volume":"377","author":"Boehme","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.medici.2016.02.002_bib0500","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00061808","article-title":"GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis","volume":"32","author":"Ling","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2334-5-62","article-title":"A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis","volume":"5","author":"Morgan","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0510","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-9-67","article-title":"Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis","volume":"9","author":"Bwanga","year":"2009","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0515","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(15)00071-7","article-title":"Clinical value of whole-genome sequencing of Mycobacterium tuberculosis","volume":"15","author":"Takiff","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0520","series-title":"Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis: policy statement","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.medici.2016.02.002_bib0525","series-title":"Anti-tuberculosis drug resistance in the world. Report number 4","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.medici.2016.02.002_bib0530","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1994.03510330043032","article-title":"Nationwide survey of drug-resistant tuberculosis in the United States","volume":"271","author":"Bloch","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.medici.2016.02.002_bib0535","series-title":"Anti-tuberculosis drug resistance in the world. The WHO\/IUATLD global project on anti-tuberculosis drug resistance surveillance","author":"World Health Organisation","year":"2010"},{"key":"10.1016\/j.medici.2016.02.002_bib0540","first-page":"19","article-title":"Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012","author":"Van der Werf","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.medici.2016.02.002_bib0545","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.drup.2014.02.003","article-title":"Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data","volume":"16","author":"Zignol","year":"2013","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.medici.2016.02.002_bib0550","series-title":"Guidelines for the programmatic management of drug-resistant tuberculosis \u2013 2011 update","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.medici.2016.02.002_bib0555","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0560","series-title":"Multidrug-resistant tuberculosis (MDR-TB) indicators: a minimum set of indicators for the programmatic management of MDR-TB in national tuberculosis control programmes","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.medici.2016.02.002_bib0565","series-title":"Electronic recording and reporting for tuberculosis care and control","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.medici.2016.02.002_bib0570","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1099\/00221287-88-2-269","article-title":"Cross-resistance relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis","volume":"88","author":"Tsukamura","year":"1975","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.medici.2016.02.002_bib0575","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2741\/1289","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"9","author":"Wade","year":"2004","journal-title":"Front Biosci J Virtual Libr"},{"key":"10.1016\/j.medici.2016.02.002_bib0580","series-title":"Guidelines for surveillance of drug resistance in tuberculosis","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.medici.2016.02.002_bib0585","first-page":"722","article-title":"Side effects of clofazimine therapy","volume":"48","author":"Ramu","year":"1976","journal-title":"Lepr India"},{"key":"10.1016\/j.medici.2016.02.002_bib0590","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem\u2013clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medici.2016.02.002_bib0595","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5588\/ijtld.11.0414","article-title":"Clinical use of the meropenem\u2013clavulanate combination for extensively drug-resistant tuberculosis [Case study]","volume":"16","author":"Payen","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medici.2016.02.002_bib0600","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","article-title":"Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis","volume":"97","author":"DeBarber","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medici.2016.02.002_bib0605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0041-3879(69)90003-8","article-title":"The ethionamide sensitivity of East African strains of Mycobacterium tuberculosis resistant to thiacetazone","volume":"50","author":"Lefford","year":"1969","journal-title":"Tubercle"},{"key":"10.1016\/j.medici.2016.02.002_bib0610","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0140-6736(91)92447-A","article-title":"Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis","volume":"337","author":"Nunn","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.medici.2016.02.002_bib0615","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1126\/science.1108379","article-title":"TB-A new target, a new drug","volume":"307","author":"Cole","year":"2005","journal-title":"Science (Washington)"},{"key":"10.1016\/j.medici.2016.02.002_bib0620","series-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.medici.2016.02.002_bib0625","doi-asserted-by":"crossref","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline","volume":"9","author":"Andries","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medici.2016.02.002_bib0630","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medici.2016.02.002_bib0635","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medici.2016.02.002_bib0640","unstructured":"Drug pipeline. Available at: http:\/\/www.newtbdrugs.org\/pipeline.php [accessed 17.05.15]."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1010660X16000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1010660X16000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T16:06:59Z","timestamp":1525709219000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010660X16000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"alternative-id":["S1010660X16000203"],"URL":"https:\/\/doi.org\/10.1016\/j.medici.2016.02.002","relation":{},"ISSN":["1010-660X"],"issn-type":[{"value":"1010-660X","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}